Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents.

Velders MA, Hofma SH, Brouwer J, de Vries CJ, Queré M, van Boven AJ.

PLoS One. 2013 Jun 3;8(6):e64424. doi: 10.1371/journal.pone.0064424. Print 2014. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/ba8e169c-a2bc-4423-b664-0de7496e453a. de Vries, Cees Jan [corrected to Vries, Cornelis Jan].

2.

Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.

Hofma SH, Brouwer J, Velders MA, van't Hof AW, Smits PC, Queré M, de Vries CJ, van Boven AJ.

J Am Coll Cardiol. 2012 Jul 31;60(5):381-7. doi: 10.1016/j.jacc.2012.01.073.

3.

Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.

Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ, van Domburg RT, Windecker S, Serruys PW.

Int J Cardiol. 2013 Dec 5;170(1):36-42. doi: 10.1016/j.ijcard.2013.10.006. Epub 2013 Oct 12.

PMID:
24196314
4.

The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.

Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Hernádez-Antolín R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vázquez N, Backx B, Serruys PW.

JACC Cardiovasc Interv. 2014 Jan;7(1):64-71. doi: 10.1016/j.jcin.2013.09.006. Epub 2013 Dec 11.

5.

Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.

Shiomi H, Kozuma K, Morimoto T, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Abe M, Suwa S, Muramatsu T, Kobayashi M, Dai K, Nakao K, Uematsu M, Tarutani Y, Fujii K, Simonton CA, Kimura T; RESET Investigators.

Circ Cardiovasc Interv. 2014 Jun;7(3):343-54. doi: 10.1161/CIRCINTERVENTIONS.113.001322. Epub 2014 May 6.

6.

Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.

Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS.

J Am Coll Cardiol. 2011 Oct 25;58(18):1844-54. doi: 10.1016/j.jacc.2011.07.031.

8.

Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register.

Kedhi E, Gomes ME, Lagerqvist B, Smith JG, Omerovic E, James S, Harnek J, Olivecrona GK.

JACC Cardiovasc Interv. 2012 Nov;5(11):1141-9. doi: 10.1016/j.jcin.2012.06.020.

9.

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators.

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.

10.

Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.

Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2013 Oct 15;112(8):1093-8. doi: 10.1016/j.amjcard.2013.05.054. Epub 2013 Jul 2.

PMID:
23827397
11.

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.

12.

Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial.

Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Seung KB, Yang TH, Lee SG, Lee JH, Seong IW, Cheong SS, Lee BK, Lee NH, Lee SW, Lee SW, Lee K, Kim HS, Jeon DS, Kim MK, Nah DY, Tahk SJ, Park SJ.

JACC Cardiovasc Interv. 2011 Oct;4(10):1096-103. doi: 10.1016/j.jcin.2011.05.024.

13.

5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.

JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.

14.

Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.

Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J.

J Interv Cardiol. 2013 Apr;26(2):153-62. doi: 10.1111/j.1540-8183.2013.12016.x. Epub 2013 Jan 31.

PMID:
23363439
15.

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH.

J Am Coll Cardiol. 2012 Apr 10;59(15):1350-61. doi: 10.1016/j.jacc.2012.01.008. Epub 2012 Feb 15.

16.

2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.

Jensen LO, Thayssen P, Christiansen EH, Tilsted HH, Maeng M, Hansen KN, Kaltoft A, Hansen HS, Bøtker HE, Krusell LR, Ravkilde J, Madsen M, Thuesen L, Lassen JF; SORT OUT IV Investigators.

J Am Coll Cardiol. 2012 Sep 25;60(13):1140-7. doi: 10.1016/j.jacc.2012.07.004. Epub 2012 Sep 5.

17.

Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial.

Hofma SH, Smits PC, Brouwer J, Velders MA, van 't Hof AW, Queré M, de Vries CJ, van Boven AJ.

EuroIntervention. 2015 Mar;10(11):1280-3. doi: 10.4244/EIJY15M01_03.

18.

Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.

Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schömig A, Mehilli J; ISAR-TEST 4 Investigators.

J Am Coll Cardiol. 2011 Sep 20;58(13):1325-31. doi: 10.1016/j.jacc.2011.06.027.

19.

Comparison of long-term outcomes between everolimus-eluting and sirolimus-eluting stents in small vessels.

Kitabata H, Loh JP, Sardi GL, Badr S, Dvir D, Barbash IM, Pendyala LK, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2013 Apr 1;111(7):973-8. doi: 10.1016/j.amjcard.2012.12.015. Epub 2013 Jan 18.

PMID:
23337837
20.

Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.

Almalla M, Schröder JW, Pross V, Marx N, Hoffmann R.

Coron Artery Dis. 2013 Mar;24(2):165-70. doi: 10.1097/MCA.0b013e32835c8fb2.

PMID:
23242011

Supplemental Content

Support Center